Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
Sung-Hsi HuangJann-Tay Wang

Abstract

Intermediate-resistance and heteroresistance to vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) is reported worldwide. A surveillance study in 2003 showed that the prevalence rates of vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) in Taiwan were 0.2% and 0.7%, respectively. This study aimed to investigate the updated prevalence of VISA and hVISA in Taiwan. MRSA isolates from sterile sites with minimal inhibitory concentrations (MICs) of 1 μg/mL or more to vancomycin were collected from 15 participating hospitals in Taiwan. Enrolled MRSA isolates were submitted to antimicrobial susceptibility testing, staphylococcal cassette chromosome mec (SCCmec) element typing, and multilocus sequence typing. Isolates with vancomycin MIC of 1 μg/mL or 2 μg/mL were screened for vancomycin heterogeneous resistance by Etest glycopeptide-resistance detection (GRD). Those with positive GRD screening results were then analyzed by modified population analysis profiling-area under the curve method for confirmation of vancomycin heteroresistance. Between 2012 and 2013, a total of 622 MRSA isolates from sterile sites with vancomycin MIC of 1 μg/mL or more were studied. The prevalence rates of hVISA and VISA amo...Continue Reading

References

Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Jan 9, 1999·The New England Journal of Medicine·S BlotF Colardyn
May 3, 2003·The Journal of Clinical Investigation·Franklin D Lowy
Nov 25, 2004·Antimicrobial Agents and Chemotherapy·Jae-Hoon SongUNKNOWN Asian Network for Surveillance of Resistant Pathogens Study Group
Nov 28, 2007·Expert Review of Anti-infective Therapy·Cindy A Loffler, Conan Macdougall
Jan 13, 2009·The Journal of Antimicrobial Chemotherapy·Steven N LeonardMichael J Rybak
Feb 16, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C-M HoJ-J Lu
Apr 23, 2010·The Journal of Antimicrobial Chemotherapy·Olivier GallonUNKNOWN Collège de Bactériologie Virologie Hygiène (ColBVH) Study Group
Nov 17, 2010·Antimicrobial Agents and Chemotherapy·Sebastiaan J van Hal, David L Paterson
Dec 31, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S J van HalI B Gosbell
Aug 23, 2011·Diagnostic Microbiology and Infectious Disease·Hongbin ChenHui Wang
Jul 4, 2012·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Shang-Yi LinPo-Liang Lu
Apr 10, 2013·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Benjamin P HowdenTimothy P Stinear
Jun 19, 2013·Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi·Yao-Sheng Chen
Jun 26, 2013·Antimicrobial Agents and Chemotherapy·Anthony M CasapaoMichael J Rybak
Aug 21, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Y-H ChenP-R Hsueh
Dec 29, 2013·Journal of Clinical Microbiology·Brandi M LimbagoValerie S Albrecht
Jul 30, 2014·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Hideaki HanakiYoshihito Niki
Dec 24, 2014·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sabrina Di GregorioMarta Mollerach

❮ Previous
Next ❯

Citations

Nov 20, 2018·Expert Review of Anti-infective Therapy·Matthew W McCarthy
Dec 24, 2019·Ci Ji Yi Xue Za Zhi = Tzu-chi Medical Journal·Hsin-Chi TsaiBing-Mu Hsu
Feb 3, 2021·Critical Reviews in Microbiology·Susana Patrícia LopesMaria Olívia Pereira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Cellulitis

Cellulitis (erysipelas) is a recurring and debilitating bacterial infection of the skin and underlying tissue. Discover the latest research on cellulitis here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.